Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

被引：0
|
作者：
Harry Raftopoulos
William Cooper
Erin O’Boyle
Nashat Gabrail
Ralph Boccia
Richard J. Gralla
机构：
[1] Hofstra North Shore-LIJ School of Medicine,Albert Einstein College of Medicine
[2] TFS International,undefined
[3] FibroGen,undefined
[4] Inc.,undefined
[5] Gabrail Cancer Center,undefined
[6] Center for Cancer and Blood Disorders,undefined
[7] Jacobi Medical Center,undefined
来源：
Supportive Care in Cancer | 2015年 / 23卷
关键词：
Cancer; Chemotherapy-induced nausea and vomiting (CINV); Extended-release; Granisetron; Subcutaneous; APF530;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：723 / 732
页数：9
相关论文
共 50 条
  • [21] Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population
    Tian, Weihua
    Wang, Zhiqiang
    Zhou, Juntian
    Zhang, Shucai
    Wang, Jinghui
    Chen, Qiang
    Huang, Cheng
    Pan, Liangxi
    Zhang, Lili
    Huang, Jianjin
    Shen, Hong
    Lin, Tongyu
    MEDICAL ONCOLOGY, 2011, 28 (01) : 71 - 78
  • [22] Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population
    Weihua Tian
    Zhiqiang Wang
    Juntian Zhou
    Shucai Zhang
    Jinghui Wang
    Qiang Chen
    Cheng Huang
    Liangxi Pan
    Lili Zhang
    Jianjin Huang
    Hong Shen
    Tongyu Lin
    Medical Oncology, 2011, 28 : 71 - 78
  • [23] Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
    Hata, Akito
    Okamoto, Isamu
    Inui, Naoki
    Okada, Morihito
    Morise, Masahiro
    Akiyoshi, Kohei
    Takeda, Masayuki
    Watanabe, Yasutaka
    Sugawara, Shunichi
    Shinagawa, Naofumi
    Kubota, Kaoru
    Saeki, Toshiaki
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 180 - +
  • [24] Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
    Mizukami, Naomi
    Yamauchi, Masanori
    Koike, Kazuhiko
    Watanabe, Akihiko
    Ichihara, Koji
    Masumori, Naoya
    Yamakage, Michiaki
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2014, 47 (03) : 542 - 550
  • [25] Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study
    Kovacs, Gabor
    Wachtel, Antonio E.
    Basharova, Elena V.
    Spinelli, Tulla
    Nicolas, Pierre
    Kabickova, Edita
    LANCET ONCOLOGY, 2016, 17 (03): : 332 - 344
  • [26] Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Sugawara, Shunichi
    Inui, Naoki
    Kanehara, Masashi
    Morise, Masahiro
    Yoshimori, Kozo
    Kumagai, Toru
    Fukui, Tomoya
    Minato, Koichi
    Iwashima, Akira
    Takeda, Yuichiro
    Kubota, Kaoru
    Saeki, Toshiaki
    Tamura, Tomohide
    CANCER, 2019, 125 (22) : 4076 - 4083
  • [27] Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist plus corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.
    Schnadig, Ian D.
    Agajanian, Richy
    Dakhil, Shaker R.
    Gabrail, Nashat Y.
    Smith, Robert E.
    Taylor, Charles W.
    Wilks, Sharon
    Cooper, William
    Mosier, Michael
    Payne, Yvette
    Klepper, Michael
    Vacirca, Jeffrey L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [28] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study
    Boice, J. A.
    Schmoll, H.
    Brown, C.
    Taylor, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
    Bernardo L. Rapoport
    Karin Jordan
    Judith A. Boice
    Arlene Taylor
    Carole Brown
    James S. Hardwick
    Alexandra Carides
    Timothy Webb
    Hans-Joachim Schmoll
    Supportive Care in Cancer, 2010, 18 : 423 - 431
  • [30] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
    Rapoport, Bernardo L.
    Jordan, Karin
    Boice, Judith A.
    Taylor, Arlene
    Brown, Carole
    Hardwick, James S.
    Carides, Alexandra
    Webb, Timothy
    Schmoll, Hans-Joachim
    SUPPORTIVE CARE IN CANCER, 2010, 18 (04) : 423 - 431
12345